A qualified provider then evaluates whether a dose adjustment, timing change, or alternative formulation would improve tolerability
"Fact Sheet: GLP-1 Pricing Agreement with Novo Nordisk and Eli Lilly." White House Briefing Room
Glucagon-like Peptide-1 (GLP-1) Agonists Market Summary The GLP-1 agonists market in the 7MM is projected to grow at a significant CAGR by 2036 in leading countries (US, EU4, UK and Japan)
Potential risks Serious risks and adverse events include: Allergic reaction to the medications or dye used in the injection Shoulder infection Depigmentation of the skin around the injection site (a whitening of the skin) Local fat atrophy around the injection site (thinning of the skin) Rupture of a tendon located in the path of the injection Nerve damage near the shoulder joint Bleeding at the injection site In addition to the above, corticosteroid injections increase the risk of: High blood pressure High blood sugar Decreased immune function Decrease in bone mineral density Bone infection (osteonecrosis) Reproductive hormone imbalance Metabolic changes (eg, increased appetite, weight gain, and fluid retention) These risks are typically associated with higher doses of corticosteroids, multiple injections, and for people with underlying medical conditions such as diabetes and heart problems
Skin Rash If you notice any of these side effects, stop your usage immediately and seek medical attention
Pompella, et al., Biochem
